Correspondence 0001193125-23-293526 from Acrivon Therapeutics, Inc. (ACRV) (CIK 0001781174) (ACRV)
Acrivon Therapeutics, Inc. (ACRV) (CIK 0001781174)
Date: Dec. 12, 2023 · CIK: 0001781174 · Accession: 0001193125-23-293526
AI Filing Summary & Sentiment
File numbers found in text: 333-275854
Letter
Re:
December 12, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-3720
Attention: Tamika N. Sheppard
Acrivon Therapeutics, Inc.
Registration Statement on Form S-3
File No. 333-275854
Acceleration Request
Requested Date: December 15, 2023
Requested Time: 4:30 P.M., Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Acrivon Therapeutics, Inc. (the “Company”), hereby requests that the effective date of the Company’s Registration Statement on Form S-3, Registration Number 333-275854 (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 4:30 P.M., Eastern Time, on December 15, 2023, or as soon thereafter as practicable or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission.
We would appreciate it if, as soon as the Registration Statement is declared effective, you would so inform Asher Rubin of Sidley Austin LLP at (410) 559-2881 or arubin@sidley.com.
Very truly yours,
/s/ Peter Blume-Jensen
Show Raw Text
CORRESP 1 filename1.htm CORRESP December 12, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Tamika N. Sheppard Re: Acrivon Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-275854 Acceleration Request Requested Date: December 15, 2023 Requested Time: 4:30 P.M., Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Acrivon Therapeutics, Inc. (the “Company”), hereby requests that the effective date of the Company’s Registration Statement on Form S-3, Registration Number 333-275854 (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 4:30 P.M., Eastern Time, on December 15, 2023, or as soon thereafter as practicable or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission. We would appreciate it if, as soon as the Registration Statement is declared effective, you would so inform Asher Rubin of Sidley Austin LLP at (410) 559-2881 or arubin@sidley.com. Very truly yours, /s/ Peter Blume-Jensen Peter Blume-Jensen President and Chief Executive Officer Acrivon Therapeutics, Inc. cc: Mary-Alice Miller, General Counsel and Corporate Secretary Asher Rubin, Sidley Austin LLP Istvan Hajdu, Sidley Austin LLP